To receive Noxxon’s real time information, please send a request to This email address is being protected from spambots. You need JavaScript enabled to view it.


The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. NOXXON disavows any obligation to update the information contained in such press releases after the date of their issuance.

Filter: NOX-A12 (olaptesed) | NOX-E36 (emapticap) | all


2017, October 03NOXXON Publishes Preclinical Proof-Of-Concept Data for Lead Compound NOX-A12 in Combination with Checkpoint Inhibitors

2017, September 28NOXXON provides update on ongoing phase 1/2 clinical trial with lead program NOX-A12

2017, July 04NOXXON announces first patients treated in phase I/II clinical trial of NOX-A12 combined with Keytruda in metastatic pancreatic and colorectal cancer

2017, May 16NOXXON Pharma announces collaboration with National Center for Tumor Diseases in Heidelberg for NOX-A12/Keytruda phase 1/2 combination trial

2016, December 15NOXXON Pharma signs clinical immuno-oncology collaboration agreement with MSD to study NOX-A12 combined with Keytruda (pembrolizumab) in pancreatic and colorectal cancer

2016, December 05NOXXON Pharma announces new preclinical data showing synergy of lead compound NOX-A12 with natural killer (NK) Cell mediated therapies

2016, October 10NOXXON Pharma demonstrates synergies between NOX-A12 and therapies working through T cells or NK cells

2014, December 05Phase IIa Results for Spiegelmer Olaptesed Pegol (NOX-A12) in MM and CLL at 2014 American Society of Hematology (ASH) Conference

2014, September 26Cell Reports Publication on the Mechanism of Action of NOXXONs Anti-SDF-1 Spiegelmer Olaptesed Pegol (NOX-A12) in Preclinical Multiple Myeloma Models

2014, September 23NOXXON Spiegelmer receives FDA Orphan Drug Designation for Glioblastoma Treatment

2014, June 13NOXXON presents Updates on Phase II Studies with Olaptesed Pegol (NOX-A12) in CLL and MM and Lexaptepid Pegol (NOX H94) in Anemic Cancer Patients

2013, December 09NOXXON presenting at ASH 2013

2012, September 26NOXXON Initiates Phase IIa Trial of anti-CXCL12/SDF-1 Spiegelmer NOX-A12 in Second Oncology Indication: Multiple Myeloma

2012, July 11NOXXON Initiates Phase IIa of anti-CXCL12/SDF-1 Spiegelmer NOX-A12 for Treatment of Chronic Lymphocytic Leukemia

2012, April 4NOXXONs NOX-A12 Delays Glioblastoma Recurrence in Preclinical Model

2011, December 12NOXXONs SDF-1 inhibitor NOX-A12 completes Phase I

2010, September 22NOXXON initiates multiple dose phase I clinical trial of SDF-1 inhibitor NOX-A12

2010, May 3NOXXON Announces the Completion of the First-in-Human Clinical Trial with Spiegelmer NOX-A 12

2009, November 2NOXXON Announces Initiation of First-in-Human Clinical Trial with Hematopoietic Stem Cell Mobilizing Spiegelmer NOX-A12

2009, September 3NOXXON Is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer NOX-A12